ANI Pharmaceuticals Reports Record Full Year Results, Reports Fourth Quarter 2017 Results, and Provides 2018 Guidance

ANI Pharmaceuticals, Inc. and Subsidiaries

Table 6: Historical Adjusted non-GAAP EBITDA Calculation and US GAAP to Non-GAAP Reconciliation

(unaudited, in thousands)

Year Ended December 31,

2015

2014

2013

   Net Income from Continuing Operations

$15,375

$28,747

$   106

Add back

   Interest expense, net

11,008

787

467

   Other (expense)/income, net

(41)

(160)

305

   Provision/(benefit) for income taxes

6,358

(9,368)

20

   Depreciation and amortization

6,900

3,878

1,110

Add back

   Stock-based compensation

3,856

3,423

36

   Merger-related expenses

-

-

5,468

         Adjusted non-GAAP EBITDA

$43,456

$27,307

$7,512